Search

Displaying results 5371 - 5380 of 10000 in total
  1. Drug

    ABBV-514

    go.drugbank.com/drugs/DB17586
    Investigational

    ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]

  2. Drug

    Pirisudanol

    go.drugbank.com/drugs/DB13412
    Experimental

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  3. Drug

    Tosufloxacin

    go.drugbank.com/drugs/DB16850
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Talampicillin

    go.drugbank.com/drugs/DB13814
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Perifosine

    go.drugbank.com/drugs/DB06641
    Investigational

    Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

  6. Drug

    Latrunculin A

    go.drugbank.com/drugs/DB02621
    Investigational

    Latrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer.

    Synonyms: LAT-A, (+)-latrunculin A
  7. Drug

    SBT-100

    go.drugbank.com/drugs/DB17215
    Experimental

    It was granted orphan drug designation by the FDA for the treatment of pancreatic cancer and osteosarcoma.[L44131,L44136]

  8. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders. … Col-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist.

  9. Drug

    Halofuginone

    go.drugbank.com/drugs/DB04866
    InvestigationalVet approved

    Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. … Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.

  10. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.